Axon (AXON) – Hot FDA News
-
Axovant Sciences (AXON) Says Intepirdine Did Not Meet its Primary Efficacy Endpoints in Phase 2b HEADWAY and pilot Phase 2 Gait and Balance Studies
-
Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy Endpoints
-
-
Back to AXON Stock Lookup